BR112015003418A2 - produto farmacêutico, conjunto, métodos para estender a duração da resposta ao tratamento, de retardar ou prevenir o desenvolvimento de resistência ao tratamento, para a seleção de uma terapia e para otimizar a eficácia terapêutica. - Google Patents
produto farmacêutico, conjunto, métodos para estender a duração da resposta ao tratamento, de retardar ou prevenir o desenvolvimento de resistência ao tratamento, para a seleção de uma terapia e para otimizar a eficácia terapêutica.Info
- Publication number
- BR112015003418A2 BR112015003418A2 BR112015003418A BR112015003418A BR112015003418A2 BR 112015003418 A2 BR112015003418 A2 BR 112015003418A2 BR 112015003418 A BR112015003418 A BR 112015003418A BR 112015003418 A BR112015003418 A BR 112015003418A BR 112015003418 A2 BR112015003418 A2 BR 112015003418A2
- Authority
- BR
- Brazil
- Prior art keywords
- treatment
- delaying
- therapy
- pharmaceutical
- duration
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
- C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
-
- G—PHYSICS
- G06—COMPUTING; CALCULATING OR COUNTING
- G06Q—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR ADMINISTRATIVE, COMMERCIAL, FINANCIAL, MANAGERIAL OR SUPERVISORY PURPOSES; SYSTEMS OR METHODS SPECIALLY ADAPTED FOR ADMINISTRATIVE, COMMERCIAL, FINANCIAL, MANAGERIAL OR SUPERVISORY PURPOSES, NOT OTHERWISE PROVIDED FOR
- G06Q30/00—Commerce
- G06Q30/02—Marketing; Price estimation or determination; Fundraising
- G06Q30/0241—Advertisements
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Business, Economics & Management (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Strategic Management (AREA)
- Development Economics (AREA)
- Accounting & Taxation (AREA)
- Finance (AREA)
- Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Wood Science & Technology (AREA)
- Genetics & Genomics (AREA)
- Pathology (AREA)
- Immunology (AREA)
- Zoology (AREA)
- Oncology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Economics (AREA)
- Theoretical Computer Science (AREA)
- General Physics & Mathematics (AREA)
- General Business, Economics & Management (AREA)
- Game Theory and Decision Science (AREA)
- Entrepreneurship & Innovation (AREA)
- Marketing (AREA)
- General Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- Microbiology (AREA)
Applications Claiming Priority (6)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201261684673P | 2012-08-17 | 2012-08-17 | |
US201261705575P | 2012-09-25 | 2012-09-25 | |
US201261706026P | 2012-09-26 | 2012-09-26 | |
US201261722725P | 2012-11-05 | 2012-11-05 | |
US201361780708P | 2013-03-13 | 2013-03-13 | |
PCT/EP2013/067050 WO2014027056A1 (en) | 2012-08-17 | 2013-08-15 | Combination therapies for melanoma comprising administering cobimetinib and vemurafinib |
Publications (1)
Publication Number | Publication Date |
---|---|
BR112015003418A2 true BR112015003418A2 (pt) | 2017-07-04 |
Family
ID=49035547
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BR112015003418A BR112015003418A2 (pt) | 2012-08-17 | 2013-08-15 | produto farmacêutico, conjunto, métodos para estender a duração da resposta ao tratamento, de retardar ou prevenir o desenvolvimento de resistência ao tratamento, para a seleção de uma terapia e para otimizar a eficácia terapêutica. |
Country Status (31)
Country | Link |
---|---|
US (3) | US11087354B2 (pt) |
EP (1) | EP2884979B1 (pt) |
JP (2) | JP6335169B2 (pt) |
KR (5) | KR20150038068A (pt) |
CN (2) | CN110251512A (pt) |
AU (1) | AU2013304021B2 (pt) |
BR (1) | BR112015003418A2 (pt) |
CA (2) | CA2879252C (pt) |
CL (1) | CL2015000345A1 (pt) |
CO (1) | CO7180225A2 (pt) |
DK (1) | DK2884979T3 (pt) |
EA (1) | EA033573B1 (pt) |
ES (1) | ES2743427T3 (pt) |
HK (1) | HK1206605A1 (pt) |
HR (1) | HRP20191533T1 (pt) |
HU (1) | HUE044789T2 (pt) |
IL (1) | IL237065B (pt) |
LT (1) | LT2884979T (pt) |
MX (1) | MX367970B (pt) |
MY (1) | MY180613A (pt) |
NZ (1) | NZ744862A (pt) |
PE (1) | PE20151156A1 (pt) |
PH (1) | PH12015500186A1 (pt) |
PL (1) | PL2884979T3 (pt) |
PT (1) | PT2884979T (pt) |
RS (1) | RS59113B1 (pt) |
SG (3) | SG10201913359TA (pt) |
SI (1) | SI2884979T1 (pt) |
UA (1) | UA114923C2 (pt) |
WO (1) | WO2014027056A1 (pt) |
ZA (1) | ZA201500348B (pt) |
Families Citing this family (19)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
SG10201913359TA (en) * | 2012-08-17 | 2020-02-27 | Hoffmann La Roche | Combination therapies for melanoma comprising administering cobimetinib and vemurafinib |
US9532987B2 (en) | 2013-09-05 | 2017-01-03 | Genentech, Inc. | Use of a combination of a MEK inhibitor and an ERK inhibitor for treatment of hyperproliferative diseases |
WO2015095842A2 (en) * | 2013-12-20 | 2015-06-25 | Biomed Valley Discoveries, Inc. | Methods and compositions for treating non-erk mapk pathway inhibitor-resistant cancers |
WO2015191986A1 (en) * | 2014-06-13 | 2015-12-17 | Genentech, Inc. | Methods of treating and preventing cancer drug resistance |
CZ2015250A3 (cs) * | 2015-04-14 | 2016-10-26 | Zentiva, K.S. | Amorfní formy vemurafenibu |
JP2018515570A (ja) * | 2015-05-22 | 2018-06-14 | プレキシコン インコーポレーテッドPlexxikon Inc. | Braf−v600関連疾患の治療に使用するためのplx−8394またはplx−7904 |
BR112017028218A2 (pt) * | 2015-06-30 | 2018-08-28 | Genentech Inc | ?comprimidos de liberação imediata contendo uma droga e processos para formação dos comprimidos? |
EP3370775B1 (en) | 2015-11-03 | 2023-04-19 | Genentech, Inc. | Combination of bcl-2 inhibitor and mek inhibitor for the treatment of cancer |
AU2016355320B2 (en) * | 2015-11-19 | 2023-12-07 | Genentech, Inc. | Methods of treating cancer using B-RAF inhibitors and immune checkpoint inhibitors |
US20180369195A1 (en) * | 2015-11-30 | 2018-12-27 | The Regents Of The University Of California | Combination therapy for treatment of melanoma |
KR20190038829A (ko) | 2016-08-12 | 2019-04-09 | 제넨테크, 인크. | Mek 억제제, pd-1 축 억제제, 및 vegf 억제제를 사용한 조합 요법 |
BR112019005815A2 (pt) | 2016-09-29 | 2019-06-25 | Genentech Inc | métodos de tratamento de um indivíduo com câncer de mama, kit para o tratamento de câncer de mama e combinação de fármacos para terapia de câncer de mama |
JP7300394B2 (ja) | 2017-01-17 | 2023-06-29 | ヘパリジェニックス ゲーエムベーハー | 肝再生の促進又は肝細胞死の低減もしくは予防のためのプロテインキナーゼ阻害 |
CN117180422A (zh) | 2017-03-02 | 2023-12-08 | 豪夫迈·罗氏有限公司 | Her2阳性乳腺癌的辅助治疗 |
WO2019139970A1 (en) * | 2018-01-09 | 2019-07-18 | Duke University | Topical administration of mek inhibiting agents for the treatment of skin disorders |
CN109879855B (zh) * | 2019-03-26 | 2021-01-05 | 中国医学科学院医药生物技术研究所 | 靶向肿瘤细胞表面pd-l1分子的抑制剂及其应用 |
JP2023525100A (ja) * | 2020-05-12 | 2023-06-14 | ノバルティス アーゲー | Craf阻害剤を含む治療的組み合わせ |
CN117940130A (zh) | 2021-03-09 | 2024-04-26 | 基因泰克公司 | 用于脑癌治疗的贝伐拉非尼 |
KR20230165795A (ko) | 2021-04-06 | 2023-12-05 | 제넨테크, 인크. | 벨바라페닙 및 코비메티닙 또는 벨바라페닙, 코비메티닙 및 아테졸리주맙을 이용한 병용 요법 |
Family Cites Families (51)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP1578346A4 (en) | 2001-12-04 | 2007-11-28 | Onyx Pharma Inc | INHIBITORS OF THE RAF-MEK-ERK PATHWAY TO TREAT CANCER |
TWI343377B (en) | 2002-03-13 | 2011-06-11 | Array Biopharma Inc | N3 alkylated benzimidazole derivatives as mek inhibitors |
US7144907B2 (en) | 2003-09-03 | 2006-12-05 | Array Biopharma Inc. | Heterocyclic inhibitors of MEK and methods of use thereof |
WO2005047542A1 (en) | 2003-10-16 | 2005-05-26 | The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Treatments for inhibiting development and progression of nevi and melanoma having braf mutations |
US7517994B2 (en) | 2003-11-19 | 2009-04-14 | Array Biopharma Inc. | Heterocyclic inhibitors of MEK and methods of use thereof |
US7732616B2 (en) | 2003-11-19 | 2010-06-08 | Array Biopharma Inc. | Dihydropyridine and dihydropyridazine derivatives as inhibitors of MEK and methods of use thereof |
CA2546486A1 (en) | 2003-11-19 | 2005-06-09 | Array Biopharma Inc. | Heterocyclic inhibitors of mek and methods of use thereof |
JP5138938B2 (ja) | 2003-12-19 | 2013-02-06 | プレキシコン インコーポレーテッド | Ret調節剤の開発のための化合物および方法 |
US7378423B2 (en) | 2004-06-11 | 2008-05-27 | Japan Tobacco Inc. | Pyrimidine compound and medical use thereof |
TW200639163A (en) | 2005-02-04 | 2006-11-16 | Genentech Inc | RAF inhibitor compounds and methods |
US20060216288A1 (en) | 2005-03-22 | 2006-09-28 | Amgen Inc | Combinations for the treatment of cancer |
RS52010B (en) | 2005-06-22 | 2012-04-30 | Plexxikon Inc. | DERIVATI PIROLO [2, 3-B] PIRIDINA KAO INHIBITORI PROTEIN KINAZE |
EP1913157B2 (en) | 2005-06-28 | 2016-10-26 | Genentech, Inc. | Egfr and kras mutations for prediction of patient response to egfr inhibitor treatment |
US8101799B2 (en) | 2005-07-21 | 2012-01-24 | Ardea Biosciences | Derivatives of N-(arylamino) sulfonamides as inhibitors of MEK |
US9095581B2 (en) | 2005-07-21 | 2015-08-04 | Ardea Biosciences, Inc. | Combinations of MEK inhibitors and Raf kinase inhibitors and uses thereof |
US7713960B2 (en) | 2005-07-22 | 2010-05-11 | University Of South Florida | Inhibition of the Raf/Mek/P-Erk pathway for treating cancer |
AU2006302415B2 (en) | 2005-10-07 | 2012-09-13 | Exelixis, Inc. | Azetidines as MEK inhibitors for the treatment of proliferative diseases |
AR062760A1 (es) * | 2006-09-13 | 2008-12-03 | Takeda Pharmaceutical | Administracion de inhibidores de dipeptidilpetidasa |
MX2009002936A (es) | 2006-09-19 | 2009-04-01 | Novartis Ag | Biomarcadores de la modulacion de objetivo, eficacia, diagnostico, y/o pronostico para los inhibidores de raf. |
EP2101759B1 (en) | 2006-12-14 | 2018-10-10 | Exelixis, Inc. | Methods of using mek inhibitors |
JP2010521154A (ja) | 2007-03-13 | 2010-06-24 | アムゲン インコーポレイティッド | K‐ras変異およびB‐raf変異ならびに抗EGFr抗体療法 |
WO2008120004A1 (en) | 2007-04-02 | 2008-10-09 | Astrazeneca Ab | Combination of a mek- inhibitor and a b-raf inhibitor for the treatment of cancer |
CA2924436A1 (en) | 2007-07-30 | 2009-02-05 | Ardea Biosciences, Inc. | Pharmaceutical combinations of n-(3,4-difluoro-2-(2-fluoro-4-iodophenylamino)-6-methoxyphenyl)-1-(2,3-dihydroxypropyl)cyclopropane-1-sulfonamide as inhibitors of mek and methods of use |
JP2011513330A (ja) | 2008-02-29 | 2011-04-28 | アレイ バイオファーマ、インコーポレイテッド | Raf阻害化合物およびその使用方法 |
AR072657A1 (es) | 2008-02-29 | 2010-09-15 | Genentech Inc | Compuestos inhibidores de raf y metodos para su uso |
CA2716949A1 (en) | 2008-02-29 | 2009-09-11 | Array Biopharma Inc. | N- (6-aminopyridin-3-yl) -3- (sulfonamido) benzamide derivatives as b-raf inhibitors for the treatment of cancer |
CA2716947A1 (en) | 2008-02-29 | 2009-09-11 | Array Biopharma Inc. | Imidazo [4,5-b] pyridine derivatives used as raf inhibitors |
UA103319C2 (en) | 2008-05-06 | 2013-10-10 | Глаксосмитклайн Ллк | Thiazole- and oxazole-benzene sulfonamide compounds |
DE102008059206A1 (de) * | 2008-11-27 | 2010-06-10 | Bayer Schering Pharma Aktiengesellschaft | Pharmazeutische Darreichungsform enthaltend Nifedipin oder Nisoldipin und einen Angiotensin-II Antagonisten und/oder ein Diuretikum |
NZ594398A (en) * | 2009-04-03 | 2014-03-28 | Plexxikon Inc | Propane-1-sulfonic acid (3-[5-(4-chloro-phenyl)-1h-pyrrol [2, 3-b] pyridine-3-carbonyl]-2,4-difluoro-phenyl} -amide compositions and uses thereof |
SG10201402917XA (en) | 2009-08-24 | 2014-08-28 | Genentech Inc | Determining sensitivity of cells to b-raf inhibitor treatment by detecting kras mutation and rtk expression levels |
AR077975A1 (es) | 2009-08-28 | 2011-10-05 | Irm Llc | Derivados de pirazol pirimidina y composiciones como inhibidores de cinasa de proteina |
BR112012008519A2 (pt) | 2009-10-12 | 2016-04-05 | Glaxosmithkline Llc | combinação |
NZ599939A (en) * | 2009-10-12 | 2014-02-28 | Hoffmann La Roche | Combinations of a pi3k inhibitor and a mek inhibitor |
WO2011104694A2 (en) * | 2010-02-26 | 2011-09-01 | GAMMAGENETICS Sàrl | Detection of braf v600e mutation by allele specific real time quantitative pcr (as-qpcr) using locked nucleic acids primers and beacon probes |
WO2011112678A1 (en) | 2010-03-09 | 2011-09-15 | Dana-Farber Cancer Institute, Inc. | Methods of diagnosing and treating cancer in patients having or developing resistance to a first cancer therapy |
US20120045433A1 (en) | 2010-08-17 | 2012-02-23 | Kapil Dhingra | Combination therapy |
US8709419B2 (en) | 2010-08-17 | 2014-04-29 | Hoffmann-La Roche, Inc. | Combination therapy |
WO2012027716A1 (en) | 2010-08-27 | 2012-03-01 | Collabrx, Inc. | Method to treat melanoma in braf inhibitor-resistant subjects |
WO2012031124A2 (en) * | 2010-09-03 | 2012-03-08 | Bristol-Myers Squibb Company | Drug formulations using water soluble antioxidants |
JP2014505658A (ja) | 2010-11-05 | 2014-03-06 | グラクソスミスクライン、インテレクチュアル、プロパティー、ナンバー2、リミテッド | 癌を治療する方法 |
WO2012068562A2 (en) | 2010-11-19 | 2012-05-24 | The Regents Of The University Of California | Compositions and methods for detection and treatment of b-raf inhibitor-resistant melanomas |
EA201390740A1 (ru) | 2010-11-19 | 2013-12-30 | Глэксосмитклайн Интеллекчуал Проперти (No.2) Лимитед | Способ лечения с использованием ингибитора braf |
US9295669B2 (en) * | 2010-12-14 | 2016-03-29 | Hoffman La-Roche Inc. | Combination therapy for proliferative disorders |
TWI505828B (zh) | 2010-12-20 | 2015-11-01 | 葛蘭素史克智慧財產(第二)有限公司 | 新穎醫藥組成物 |
AR085279A1 (es) | 2011-02-21 | 2013-09-18 | Plexxikon Inc | Formas solidas de {3-[5-(4-cloro-fenil)-1h-pirrolo[2,3-b]piridina-3-carbonil]-2,4-difluor-fenil}-amida del acido propano-1-sulfonico |
WO2012145503A1 (en) | 2011-04-21 | 2012-10-26 | Novartis Ag | Pharmaceutical combinations |
US20130172375A1 (en) | 2011-12-13 | 2013-07-04 | Hoffmann-La Roche Inc. | Pharmaceutical composition |
US9216170B2 (en) | 2012-03-19 | 2015-12-22 | Hoffmann-La Roche Inc. | Combination therapy for proliferative disorders |
SG10201913359TA (en) * | 2012-08-17 | 2020-02-27 | Hoffmann La Roche | Combination therapies for melanoma comprising administering cobimetinib and vemurafinib |
WO2014128235A1 (en) | 2013-02-22 | 2014-08-28 | F. Hoffmann-La Roche Ag | Methods of treating cancer and preventing drug resistance |
-
2013
- 2013-08-15 SG SG10201913359TA patent/SG10201913359TA/en unknown
- 2013-08-15 KR KR1020157003834A patent/KR20150038068A/ko active Search and Examination
- 2013-08-15 CA CA2879252A patent/CA2879252C/en active Active
- 2013-08-15 KR KR1020177009790A patent/KR20170044759A/ko active Search and Examination
- 2013-08-15 KR KR1020197014117A patent/KR20190057421A/ko active Application Filing
- 2013-08-15 AU AU2013304021A patent/AU2013304021B2/en active Active
- 2013-08-15 CN CN201910437096.0A patent/CN110251512A/zh active Pending
- 2013-08-15 CA CA2928396A patent/CA2928396A1/en not_active Abandoned
- 2013-08-15 WO PCT/EP2013/067050 patent/WO2014027056A1/en active Application Filing
- 2013-08-15 UA UAA201501710A patent/UA114923C2/uk unknown
- 2013-08-15 SG SG10201708494QA patent/SG10201708494QA/en unknown
- 2013-08-15 PL PL13753131T patent/PL2884979T3/pl unknown
- 2013-08-15 RS RS20191053A patent/RS59113B1/sr unknown
- 2013-08-15 HU HUE13753131 patent/HUE044789T2/hu unknown
- 2013-08-15 BR BR112015003418A patent/BR112015003418A2/pt not_active IP Right Cessation
- 2013-08-15 PT PT13753131T patent/PT2884979T/pt unknown
- 2013-08-15 KR KR1020227041809A patent/KR20220165811A/ko not_active IP Right Cessation
- 2013-08-15 JP JP2015526987A patent/JP6335169B2/ja active Active
- 2013-08-15 MY MYPI2015700457A patent/MY180613A/en unknown
- 2013-08-15 KR KR1020217027317A patent/KR20210108502A/ko not_active IP Right Cessation
- 2013-08-15 MX MX2015002031A patent/MX367970B/es active IP Right Grant
- 2013-08-15 US US13/967,782 patent/US11087354B2/en active Active
- 2013-08-15 DK DK13753131.5T patent/DK2884979T3/da active
- 2013-08-15 EA EA201590262A patent/EA033573B1/ru not_active IP Right Cessation
- 2013-08-15 NZ NZ744862A patent/NZ744862A/en unknown
- 2013-08-15 SI SI201331565T patent/SI2884979T1/sl unknown
- 2013-08-15 SG SG11201500582UA patent/SG11201500582UA/en unknown
- 2013-08-15 ES ES13753131T patent/ES2743427T3/es active Active
- 2013-08-15 PE PE2015000215A patent/PE20151156A1/es not_active Application Discontinuation
- 2013-08-15 CN CN201380042815.XA patent/CN104640545A/zh active Pending
- 2013-08-15 LT LTEP13753131.5T patent/LT2884979T/lt unknown
- 2013-08-15 EP EP13753131.5A patent/EP2884979B1/en active Active
-
2015
- 2015-01-16 ZA ZA2015/00348A patent/ZA201500348B/en unknown
- 2015-01-27 CO CO15016085A patent/CO7180225A2/es unknown
- 2015-01-28 PH PH12015500186A patent/PH12015500186A1/en unknown
- 2015-02-02 IL IL237065A patent/IL237065B/en active IP Right Grant
- 2015-02-13 CL CL2015000345A patent/CL2015000345A1/es unknown
- 2015-07-27 HK HK15107148.9A patent/HK1206605A1/xx unknown
-
2017
- 2017-04-06 JP JP2017075880A patent/JP2017160214A/ja active Pending
-
2019
- 2019-08-27 HR HRP20191533 patent/HRP20191533T1/hr unknown
-
2021
- 2021-08-09 US US17/444,691 patent/US11783366B2/en active Active
-
2023
- 2023-08-17 US US18/451,452 patent/US20240046303A1/en active Pending
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
BR112015003418A2 (pt) | produto farmacêutico, conjunto, métodos para estender a duração da resposta ao tratamento, de retardar ou prevenir o desenvolvimento de resistência ao tratamento, para a seleção de uma terapia e para otimizar a eficácia terapêutica. | |
IL260383B (en) | Low dose medication | |
BR112013011968A2 (pt) | composição farmacêutica, métodos de tratamento e usos da mesma | |
IL265774B (en) | Diagnosis, prevention and treatment of joint diseases | |
DK2986304T3 (da) | Farmaceutisk sammensætning, fremgangsmåder til behandling og anvendelser deraf. | |
BR112014023937A2 (pt) | composição farmacêutica, agente farmacêutico de combinação e método de tratamento | |
BR112014004181A2 (pt) | composto, composição farmacêutica, e, método de tratamento, prevenção, e / ou retardo do início de uma doença ou patologia | |
BR112016018062A2 (pt) | compostos terapêuticos, composição farmacêutica e usos | |
BR112015003397A2 (pt) | composto, composição farmacêutica, uso do composto e método para tratar uma doença ou condição mediada por rorgammat em um paciente. | |
BR112015023203A8 (pt) | métodos para tratamento de câncer, método para aumentar a eficiência de um tratamento de câncer, método para retardar e/ou prevenir o desenvolvimento de câncer, método para tratar um indivíduo com câncer, método para aumentar a sensibilidade para um agente de terapia para câncer, método para estender um período de sensibilidade e método para estender a duração da resposta para uma terapia para câncer. | |
IL253441A0 (en) | A medicine for the prevention and/or treatment of polycystic kidney disease | |
HK1256754B (zh) | 新念珠藻素化合物和綴合物、它們的製備以及它們的治療用途 | |
ZA201802033B (en) | Heteroaryl compounds and their use as therapeutic drugs | |
EP3156055A4 (en) | Pharmaceutical composition for preventing or treating muscular weakness-related diseases, containing butylpyridinium or derivative thereof | |
BR112017013012A2 (pt) | compostos de indenil, composições farmacêuticas e usos médicos destes | |
EP3239133A4 (en) | Dream neuronal calcium sensor-modulating compounds, and therapeutic uses thereof | |
IL246286B (en) | A medical preparation for the prevention and treatment of advanced myopia. | |
EP3220920A4 (en) | Combination therapy effective against microorganisms, including drug resistant microorganisms | |
EP3046556A4 (en) | Combination drug therapy | |
EP2949326A4 (en) | MOLECULAR FIXED COMBINATION ACTIVE FOR TUMOR THERAPY AND PREVENTION | |
EP3075380A4 (en) | Drug for treating vertebrae cervicales and lumber diseases | |
HRP20182167T1 (hr) | Derivati benzilhidroksida, njihova priprava i njihova terapeutska uporaba | |
AU2012903813A0 (en) | Determination, prescription and administration of personalised dose of exercise |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
B06F | Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette] | ||
B06F | Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette] | ||
B06I | Publication of requirement cancelled [chapter 6.9 patent gazette] |
Free format text: ANULADA A PUBLICACAO CODIGO 6.6.1 NA RPI NO 2462 DE 13/03/2018 POR TER SIDO INDEVIDA. |
|
B07D | Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette] |
Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001, QUE MODIFICOU A LEI NO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUENCIA PREVIA DA ANVISA. CONSIDERANDO A APROVACAO DOS TERMOS DO PARECER NO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDENCIAS CABIVEIS. |
|
B08F | Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette] |
Free format text: REFERENTE A 6A ANUIDADE. |
|
B08K | Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette] |
Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2527 DE 11-06-2019 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013. |